Roswell Park experts will share new discoveries and insights at the 2025 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) Feb. 12-15 in Honolulu.
Researchers at Albert Einstein College of Medicine, Roswell Park Comprehensive Cancer Center and the Icahn School of Medicine at Mount Sinai have found that bacterial vaginosis consists of two distinct subtypes 鈥� one of which significantly increases the risk of developing chlamydia infections
Researchers at Roswell Park Comprehensive Cancer Center have identified a cause of resistance to doxorubicin in triple-negative breast cancer. The team鈥檚 new study in Scientific Reports points to a new strategy for overcoming this resistance to treatment, using drugs known as IMPDH2 inhibitors.
As the year comes to a close, Roswell Park Comprehensive Cancer Center honors the 143 physicians across 35 specialties named to Buffalo Spree magazine鈥檚 Top Doctors list for 2025. The annual list is compiled through surveys submitted by Western New York physicians.
A team of researchers at Roswell Park , led by Dhyan Chandra, PhD, has discovered a new therapeutic target for neuroendocrine prostate cancer, a rare and hard-to-treat form of prostate cancer. Their findings, newly published in the journal Oncogene, suggest that a set of processes known as the mitochondrial unfolded protein response, could be an Achilles鈥� heel for this often-deadly cancer type, and may point the way to a new treatment approach.
Governor Kathy Hochul today celebrated the opening of the Roswell Park GMP Engineering and Cell Manufacturing Facility, New York's first cell and gene therapy hub, located at Roswell Park Comprehensive Cancer Center in Buffalo. The $98 million facility will create new jobs, help to support the research and development of life-saving cell and gene therapies at Roswell, significantly grow its well-established research capabilities, and establish Roswell as one of the premier cell therapy discovery and development institutions in the nation. The expansion also realizes Governor Hochul鈥檚 2023 State of the State commitment to bolster the state鈥檚 leadership in the fast-growing CGT sector through establishment of an Upstate cell and gene therapy hub to catalyze its growth in western NY. The GEM facility meets U.S. FDA Good Manufacturing Practice standards for manufacture of clinical cell therapy products, positioning the Roswell Park team to be a multifaceted resource for patients, care teams
A study led by Roswell Park provides new insight into the complex interactions of the 鈥渢umor-immune-gut axis,鈥� and its role in influencing immunotherapy responses in patients with recurrent ovarian cancer. Newly published in Nature Communications, the findings emphasize the role of the patient鈥檚 microbiome 鈥� the collection of microorganisms in the body 鈥攁nd lay the groundwork for future clinical trials aimed at improving treatment outcomes.
About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax. Their findings, to be presented during a talk today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California, provide strong preclinical evidence that adding venetoclax to standard treatment may improve outcomes in patients with treatment-resistant B-cell lymphomas.
Researchers from Roswell Park Comprehensive Cancer Center will present compelling findings showcasing significant benefits of resistance training for patients with multiple myeloma, in a talk at the 66th American Society of Hematology (ASH) Annual Meeting. The study, led by Jens Hillengass, MD, PhD, and Janine Joseph, MS, MBA, presents new evidence documenting that targeted exercise regimens can alleviate fatigue, improve sleep and reduce pain, offering new hope for enhancing quality of life in cancer care.
The results of two important lymphoma studies led by experts at Roswell Park Comprehensive Cancer Center will be presented during oral abstract sessions this morning at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California. Lymphoma is a type of blood cancer that causes white blood cells called lymphocytes to grow out of control and behave abnormally.
A preclinical study led by a faculty member at Roswell Park Comprehensive Cancer Center shows that gilteritinib (brand name Xospata), a targeted cancer treatment, can strengthen chimeric antigen receptor (CAR) T-cell immunotherapy in two high-risk pediatric leukemias that have poor survival rates 鈥� FLT3-mutated acute myeloid leukemia (AML) and KMT2A-rearranged acute lymphoblastic leukemia (ALL). Lisa Niswander, MD, PhD, Assistant Professor of Oncology in the Department of Pediatric Oncology, will deliver the results this afternoon in an oral abstract session at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California.
Research out of Roswell Park Comprehensive Cancer Center has shed light on how the drug venetoclax (brand name Venclexta) works synergistically with CAR T-cell immunotherapy to combat chronic lymphocytic leukemia (CLL), the most common type of leukemia in the U.S. Matthew Cortese, MD, MPH, Assistant Professor of Oncology in Roswell Park鈥檚 departments of Medicine and Cancer Genetics & Genomics, is first author of the study, which he will present during an oral abstract session today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California.
Roswell Park President and CEO Candace S. Johnson, PhD, today introduced the cancer center鈥檚 first Physician in Chief 鈥斺�痑nd the slate of experts appointed to tackle the most pressing opportunities and challenges related to cancer treatment, outcomes and delivery of care.
A widely accessible drug commonly used to control blood glucose levels in diabetic patients has the potential to strengthen the effects of immunotherapy and improve recurrence-free survival in people with lung cancer who are overweight or obese, according to a recently published article in the Journal of the National Cancer Institute.
Roswell Park, in partnership with the University at Buffalo (UB) School of Nursing, has received a five-year, $2.11 million Institutional Clinical Scientist Awards (K12) grant from the National Cancer Institute to establish a training program for nurse-scientists focused around clinical translational research
Roswell Park experts representing various specialties will highlight innovative research and advancements in hematology and hematologic cancers at the 66th annual meeting of the American Society of Hematology (ASH), to be held December 7-10 in San Diego, California.
A new treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a phase 1 clinical trial for patients with triple-negative breast cancer (TNBC), the most aggressive type of breast cancer. Results of the study are newly reported in The Journal for ImmunoTherapy of Cancer.
The Roswell Park team has developed a new method to measure mutation loads across species, revealing the role of the "dark genome" 鈥� ancient, virus-like genes that affect cellular function. The findings support further exploration of antiviral drugs as potential tools to target the dark genome in controlling cancer.
Updated results from a phase 3 clinical trial are expected to change the way advanced stage classic Hodgkin lymphoma (cHL) is treated. Details appear in a study published today in The New England Journal of Medicine. Drs. Kara Kelly of Roswell Park Comprehensive Cancer Center and Sharon Castellino of Children鈥檚 Healthcare of Atlanta and Emory University School of Medicine/Winship Cancer Institute of Emory University served as pediatric leads of this important trial in children and adults with lymphoma.
The Clinical Leukemia Service at Roswell Park Comprehensive Cancer Center helped lead the first clinical trial of the experimental oral drug ziftomenib in patients with acute myeloid leukemia (AML).
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 海角社区 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right